A detailed history of Ever Source Wealth Advisors, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Ever Source Wealth Advisors, LLC holds 77 shares of CRNX stock, worth $4,593. This represents 0.0% of its overall portfolio holdings.

Number of Shares
77
Previous 67 14.93%
Holding current value
$4,593
Previous $3,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$43.83 - $54.98 $438 - $549
10 Added 14.93%
77 $3,000
Q2 2024

Aug 13, 2024

BUY
$42.12 - $51.91 $1,389 - $1,713
33 Added 97.06%
67 $3,000
Q1 2024

Jun 11, 2024

SELL
$34.76 - $46.81 $2,954 - $3,978
-85 Reduced 71.43%
34 $1,000
Q4 2023

Feb 09, 2024

BUY
$25.62 - $37.07 $1,998 - $2,891
78 Added 190.24%
119 $4,000
Q3 2023

Nov 03, 2023

BUY
$15.97 - $30.59 $654 - $1,254
41 New
41 $1,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $3.21B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Ever Source Wealth Advisors, LLC Portfolio

Follow Ever Source Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ever Source Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ever Source Wealth Advisors, LLC with notifications on news.